ADMA Biologics, Inc. [NASDAQ:ADMA]: Analyst Rating and Earnings

Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to ADMA Biologics, Inc. [ADMA] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give ADMA an Outperform rating. Its stock price has been found in the range of 2.08 to 6.96. This is compared to its latest closing price of $3.78.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for ADMA Biologics, Inc. [ADMA] is sitting at 1.86. This is compared to 1 month ago, when its average rating was 1.86.

Pay attention to the next-scheduled financial results for this company to be released, which is slated for Fri 9 Aug (In 59 Days).

Fundamental Analysis of ADMA Biologics, Inc. [ADMA]

Now let’s turn to look at profitability: with a current Operating Margin for ADMA Biologics, Inc. [ADMA] sitting at -331.99 and its Gross Margin at -153.39.

Turning to investigate this organization’s capital structure, ADMA Biologics, Inc. [ADMA] has generated a Total Debt to Total Equity ratio of 223.69. Similarly, its Total Debt to Total Capital is 69.11, while its Total Debt to Total Assets stands at 49.76. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 223.54, and its Long-Term Debt to Total Capital is 69.06. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -4.64. The Enterprise Value to Sales for this firm is now 14.92, and its Total Debt to Enterprise Value stands at 0.34. ADMA Biologics, Inc. [ADMA] has a Price to Book Ratio of 5.60.

Shifting the focus to workforce efficiency, ADMA Biologics, Inc. [ADMA] earns $53,413 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.44 and its Total Asset Turnover is 0.17. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.69 and its Current Ratio is 4.63. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

ADMA Biologics, Inc. [ADMA] has 57.46M shares outstanding, amounting to a total market cap of $216.62M. Its stock price has been found in the range of 2.08 to 6.96. At its current price, it has moved by -45.83% from its 52-week high, and it has moved 81.25% from its 52-week low.

This stock’s Beta value is currently 2.85, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 32.41. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is ADMA Biologics, Inc. [ADMA] a Reliable Buy?

ADMA Biologics, Inc. [ADMA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.